| pubmed-article:11043420 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C1556085 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C0024301 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C0079747 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C0879399 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:11043420 | lifeskim:mentions | umls-concept:C0295415 | lld:lifeskim |
| pubmed-article:11043420 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:11043420 | pubmed:dateCreated | 2000-10-23 | lld:pubmed |
| pubmed-article:11043420 | pubmed:abstractText | The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma. | lld:pubmed |
| pubmed-article:11043420 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11043420 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11043420 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11043420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11043420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11043420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11043420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11043420 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11043420 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:11043420 | pubmed:issn | 0939-5555 | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:HillerEE | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:HiddemannWW | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:EngertAA | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:GramatzkiMM | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:AtzpodienJJ | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:BruggerWW | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:HallekMM | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:UnterhaltMM | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:OstermannHH | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:KnebaMM | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:TrümperLL | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:Feuring-Buske... | lld:pubmed |
| pubmed-article:11043420 | pubmed:author | pubmed-author:AulitzkyEE | lld:pubmed |
| pubmed-article:11043420 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11043420 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:11043420 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11043420 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11043420 | pubmed:pagination | 493-500 | lld:pubmed |
| pubmed-article:11043420 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:meshHeading | pubmed-meshheading:11043420... | lld:pubmed |
| pubmed-article:11043420 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11043420 | pubmed:articleTitle | IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. | lld:pubmed |
| pubmed-article:11043420 | pubmed:affiliation | Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University of München, Germany. | lld:pubmed |
| pubmed-article:11043420 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11043420 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11043420 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11043420 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11043420 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11043420 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11043420 | lld:pubmed |
